Frequency and characteristics of occult hepatitis b infection among hepatocellular carcinoma patients in japan

Jun Muto, Masaya Sugiyama, Ken Shirabe, Motokazu Mukaide, Ikue Kirikae-Muto, Toru Ikegami, Tomoharu Yoshizumi, Yo Ichi Yamashita, Yoshihiko Maehara, Masashi Mizokami

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction and aim. Occult hepatitis B virus (HBV) infection (OBI) represents a state without detectable hepatitis B surface antigen, but positive for HBV DNA. The correlation between OBI and hepatocellular carcinoma (HCC) carcinogenesis is controversial. We studied the frequency and characteristics of OBI among HCC patients and metastatic liver cancer patients. Material and methods. DNA was obtained from tumor and non-tumor tissues from 75 HCC patients (15 chronic hepatitis B (CHB), 39 chronic hepatitis C (CHC), 21 cryptogenic) and 15 metastatic liver cancer patients who underwent liver resection. HBV DNA and covalently-closed circular (ccc) DNA were detected using real-time polymerase chain reaction (PCR), and four HBV DNA regions were detected by nested PCR. Clinicopathological factors were compared between patients with and without OBI. Results. HBV DNA was detected in 14 (93.3%) CHB, five (22.7%) cryptogenic and four (10.3%) CHC patients. cccDNA was detected in 12 (80.0%) CHB, three (14.3%) cryptogenic and two (5.1%) CHC patients. All CHB, eight (38.1%) cryptogenic and ten (25.6%) CHC patients tested positive with nested PCR. No metastatic liver cancer patients were positive for any HBV DNA regions. OBI patients had shorter prothrombin times (P = 0.0055), and lower inflammation activity score in non-tumor liver (P = 0.0274). There were no differences in anti-HBV antibodies. Conclusions. OBI was detected in 38% of cryptogenic and 25.6% of CHC patients. There was no correlation between OBI and anti-HBV antibodies, but fewer patients with OBI had high inflammatory activity, suggesting that factors other than inflammation may be involved in HCC carcinogenesis in patients with OBI.

Original languageEnglish
Pages (from-to)596-603
Number of pages8
JournalAnnals of Hepatology
Volume17
Issue number4
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Hepatitis
Hepatocellular Carcinoma
Japan
Infection
Hepatitis B virus
Chronic Hepatitis C
Chronic Hepatitis B
DNA
Liver Neoplasms
Hepatitis B Antibodies
Carcinogenesis
Inflammation
Circular DNA
Polymerase Chain Reaction
Liver
Prothrombin Time
Virus Diseases
Chronic Hepatitis
Hepatitis B Surface Antigens
Real-Time Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Frequency and characteristics of occult hepatitis b infection among hepatocellular carcinoma patients in japan. / Muto, Jun; Sugiyama, Masaya; Shirabe, Ken; Mukaide, Motokazu; Kirikae-Muto, Ikue; Ikegami, Toru; Yoshizumi, Tomoharu; Yamashita, Yo Ichi; Maehara, Yoshihiko; Mizokami, Masashi.

In: Annals of Hepatology, Vol. 17, No. 4, 01.07.2018, p. 596-603.

Research output: Contribution to journalArticle

Muto, J, Sugiyama, M, Shirabe, K, Mukaide, M, Kirikae-Muto, I, Ikegami, T, Yoshizumi, T, Yamashita, YI, Maehara, Y & Mizokami, M 2018, 'Frequency and characteristics of occult hepatitis b infection among hepatocellular carcinoma patients in japan', Annals of Hepatology, vol. 17, no. 4, pp. 596-603. https://doi.org/10.5604/01.3001.0012.0927
Muto, Jun ; Sugiyama, Masaya ; Shirabe, Ken ; Mukaide, Motokazu ; Kirikae-Muto, Ikue ; Ikegami, Toru ; Yoshizumi, Tomoharu ; Yamashita, Yo Ichi ; Maehara, Yoshihiko ; Mizokami, Masashi. / Frequency and characteristics of occult hepatitis b infection among hepatocellular carcinoma patients in japan. In: Annals of Hepatology. 2018 ; Vol. 17, No. 4. pp. 596-603.
@article{63bf5948fad8415f92737ff1df651a16,
title = "Frequency and characteristics of occult hepatitis b infection among hepatocellular carcinoma patients in japan",
abstract = "Introduction and aim. Occult hepatitis B virus (HBV) infection (OBI) represents a state without detectable hepatitis B surface antigen, but positive for HBV DNA. The correlation between OBI and hepatocellular carcinoma (HCC) carcinogenesis is controversial. We studied the frequency and characteristics of OBI among HCC patients and metastatic liver cancer patients. Material and methods. DNA was obtained from tumor and non-tumor tissues from 75 HCC patients (15 chronic hepatitis B (CHB), 39 chronic hepatitis C (CHC), 21 cryptogenic) and 15 metastatic liver cancer patients who underwent liver resection. HBV DNA and covalently-closed circular (ccc) DNA were detected using real-time polymerase chain reaction (PCR), and four HBV DNA regions were detected by nested PCR. Clinicopathological factors were compared between patients with and without OBI. Results. HBV DNA was detected in 14 (93.3{\%}) CHB, five (22.7{\%}) cryptogenic and four (10.3{\%}) CHC patients. cccDNA was detected in 12 (80.0{\%}) CHB, three (14.3{\%}) cryptogenic and two (5.1{\%}) CHC patients. All CHB, eight (38.1{\%}) cryptogenic and ten (25.6{\%}) CHC patients tested positive with nested PCR. No metastatic liver cancer patients were positive for any HBV DNA regions. OBI patients had shorter prothrombin times (P = 0.0055), and lower inflammation activity score in non-tumor liver (P = 0.0274). There were no differences in anti-HBV antibodies. Conclusions. OBI was detected in 38{\%} of cryptogenic and 25.6{\%} of CHC patients. There was no correlation between OBI and anti-HBV antibodies, but fewer patients with OBI had high inflammatory activity, suggesting that factors other than inflammation may be involved in HCC carcinogenesis in patients with OBI.",
author = "Jun Muto and Masaya Sugiyama and Ken Shirabe and Motokazu Mukaide and Ikue Kirikae-Muto and Toru Ikegami and Tomoharu Yoshizumi and Yamashita, {Yo Ichi} and Yoshihiko Maehara and Masashi Mizokami",
year = "2018",
month = "7",
day = "1",
doi = "10.5604/01.3001.0012.0927",
language = "English",
volume = "17",
pages = "596--603",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "4",

}

TY - JOUR

T1 - Frequency and characteristics of occult hepatitis b infection among hepatocellular carcinoma patients in japan

AU - Muto, Jun

AU - Sugiyama, Masaya

AU - Shirabe, Ken

AU - Mukaide, Motokazu

AU - Kirikae-Muto, Ikue

AU - Ikegami, Toru

AU - Yoshizumi, Tomoharu

AU - Yamashita, Yo Ichi

AU - Maehara, Yoshihiko

AU - Mizokami, Masashi

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Introduction and aim. Occult hepatitis B virus (HBV) infection (OBI) represents a state without detectable hepatitis B surface antigen, but positive for HBV DNA. The correlation between OBI and hepatocellular carcinoma (HCC) carcinogenesis is controversial. We studied the frequency and characteristics of OBI among HCC patients and metastatic liver cancer patients. Material and methods. DNA was obtained from tumor and non-tumor tissues from 75 HCC patients (15 chronic hepatitis B (CHB), 39 chronic hepatitis C (CHC), 21 cryptogenic) and 15 metastatic liver cancer patients who underwent liver resection. HBV DNA and covalently-closed circular (ccc) DNA were detected using real-time polymerase chain reaction (PCR), and four HBV DNA regions were detected by nested PCR. Clinicopathological factors were compared between patients with and without OBI. Results. HBV DNA was detected in 14 (93.3%) CHB, five (22.7%) cryptogenic and four (10.3%) CHC patients. cccDNA was detected in 12 (80.0%) CHB, three (14.3%) cryptogenic and two (5.1%) CHC patients. All CHB, eight (38.1%) cryptogenic and ten (25.6%) CHC patients tested positive with nested PCR. No metastatic liver cancer patients were positive for any HBV DNA regions. OBI patients had shorter prothrombin times (P = 0.0055), and lower inflammation activity score in non-tumor liver (P = 0.0274). There were no differences in anti-HBV antibodies. Conclusions. OBI was detected in 38% of cryptogenic and 25.6% of CHC patients. There was no correlation between OBI and anti-HBV antibodies, but fewer patients with OBI had high inflammatory activity, suggesting that factors other than inflammation may be involved in HCC carcinogenesis in patients with OBI.

AB - Introduction and aim. Occult hepatitis B virus (HBV) infection (OBI) represents a state without detectable hepatitis B surface antigen, but positive for HBV DNA. The correlation between OBI and hepatocellular carcinoma (HCC) carcinogenesis is controversial. We studied the frequency and characteristics of OBI among HCC patients and metastatic liver cancer patients. Material and methods. DNA was obtained from tumor and non-tumor tissues from 75 HCC patients (15 chronic hepatitis B (CHB), 39 chronic hepatitis C (CHC), 21 cryptogenic) and 15 metastatic liver cancer patients who underwent liver resection. HBV DNA and covalently-closed circular (ccc) DNA were detected using real-time polymerase chain reaction (PCR), and four HBV DNA regions were detected by nested PCR. Clinicopathological factors were compared between patients with and without OBI. Results. HBV DNA was detected in 14 (93.3%) CHB, five (22.7%) cryptogenic and four (10.3%) CHC patients. cccDNA was detected in 12 (80.0%) CHB, three (14.3%) cryptogenic and two (5.1%) CHC patients. All CHB, eight (38.1%) cryptogenic and ten (25.6%) CHC patients tested positive with nested PCR. No metastatic liver cancer patients were positive for any HBV DNA regions. OBI patients had shorter prothrombin times (P = 0.0055), and lower inflammation activity score in non-tumor liver (P = 0.0274). There were no differences in anti-HBV antibodies. Conclusions. OBI was detected in 38% of cryptogenic and 25.6% of CHC patients. There was no correlation between OBI and anti-HBV antibodies, but fewer patients with OBI had high inflammatory activity, suggesting that factors other than inflammation may be involved in HCC carcinogenesis in patients with OBI.

UR - http://www.scopus.com/inward/record.url?scp=85049642770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049642770&partnerID=8YFLogxK

U2 - 10.5604/01.3001.0012.0927

DO - 10.5604/01.3001.0012.0927

M3 - Article

C2 - 29893701

AN - SCOPUS:85049642770

VL - 17

SP - 596

EP - 603

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 4

ER -